<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZALCITABINE (DDC, DIDEOXYCYTIDINE)</span><br/>(zal-cit'a-been)<br/><span class="topboxtradename">Hivid<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Lamivudine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.375 mg, 0.75 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>A synthetic pyrimidine nucleotide that inhibits the replication of HIV by inhibition of viral DNA synthesis. It appears to
         act by becoming incorporated into the DNA chains of the HIV virus during viral replication.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Zalcitabine is able to decrease the HIV viral load by its antiviral properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Combination therapy with zidovudine for AIDS. Second-line monotherapy for AIDS.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Can be used in children.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to zalcitabine.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate to severe neuropathy; history of pancreatitis; CHF, cardiomyopathy; renal impairment, hepatic impairment, alcohol
         abuse; pregnancy (category C). It is not known if zalcitabine is excreted in breast milk. Safety and effectiveness in HIV-infected
         children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Combination Therapy for HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.75 mg q8h given with zidovudine 200 mg q8h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.015 to 0.04 mg/kg q6h for 8 wk, after 8 wk of monotherapy an alternating regimen of zalcitabine and zidovudine is begun
               (4-wk cycle of zidovudine for 3 wk and zalcitabine for 1 wk)<br/><br/><span class="indicationtitle">Monotherapy for HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.01 mg/kg q8h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach.</li>
<li>Store at 15°30° C (56°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> May exacerbate existing CHF and cardiomyopathy. <span class="typehead">CNS:</span> <span class="speceff-common">Peripheral neuropathy,</span> numbness. <span class="typehead">GI:</span> Diarrhea, mouth and esophageal ulcers, <span class="speceff-life">pancreatitis</span>, may exacerbate existing hepatic dysfunction. <span class="typehead">Hematologic:</span> Neutropenia, thrombocytopenia.  <span class="typehead">Skin:</span> <span class="speceff-common">Transient symptom complex of cutaneous eruptions (maculovesicular in nature), fever, malaise, and aphthous mouth ulcers,</span> arthralgia, urticaria, <span class="speceff-life">anaphylaxis</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May cause additive peripheral neuropathy with <b>didanosine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 2 wk. <span class="typehead">Distribution:</span> Distributes somewhat into CSF. <span class="typehead">Metabolism:</span> Does not appear to be metabolized.  <span class="typehead">Elimination:</span> 62% excreted unchanged in urine.  <span class="typehead">Half-Life:</span> 1.21.8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue drug and promptly notify physician if patient experiences numbness, tingling, burning, or pain in extremities.</li>
<li>Lab tests: Baseline and periodic tests for serum amylase, serum glucose, triglycerides, and serum calcium levels; monitor
            closely in patients with history of pancreatitis or elevated serum amylase.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician promptly S&amp;S of pancreatitis and peripheral neuropathy (see Appendix F).</li>
<li>Use contraception while taking zalcitabine.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>